BioSpace News Archive

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the Phase II CONTROL trial with the neratinib treatment arm of the ExteNET Trial

Based in Fort Worth, Texas, Sanara MedTech Inc., a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced that it has closed an exclusive partnership with Pixalere Healthcare Inc..

Strata Oncology ® , Inc ., a precision oncology company advancing molecular indications for cancer therapies, today announced the results of a study focused on evaluating a novel biomarker approach for immunotherapy

InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, presented the latest clinical data for the pan-FGFR inhibitor gunagratinib today at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. This is the first time InnoCare has presented gunagratinib’s clinical data at an international academic conference, showing good safety and tolerability.

In large observational study, CHOP researchers find ADHD drugs are associated with less suicidal behavior and thoughts in preadolescent children with substantial externalizing behaviors like hyperactivity and oppositional defiance

Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting being held virtually June 4-8, 2021.

Sky Medical Technology (Sky), a UK-based medical device manufacturer, today announced the inclusion of its flagship product, the geko™ device, on a U.S. Veterans Health Administration (VA) Federal Supply Schedule (FSS) contract awarded to its federal distribution partner, Marathon Medical Inc.

A study led by researchers at Yale Cancer Center, Stony Brook University, and KDx Diagnostics, Inc., examined a revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine

The market is estimated to grow with a CAGR of 7.2% from 2019-2027.

The growth of the market is attributed to increasing demand for tumor modelling and biobanking, escalating adoption of personalized drugs, and growing focus on developing alternatives for animal testing models.